H3n2 Infection Pipeline Insight

DelveInsight’s, “H3N2 Infection - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in H3N2 Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

H3N2 Infection Understanding

H3N2 Infection: Overview

H3N2 viruses have circulated in humans since their pandemic emergence in 1968 and are generally associated with uncomplicated disease in young healthy adults. However, epidemics caused by H3N2 viruses have been more severe than those caused by seasonal H1N1 or influenza B viruses. Influenza viruses that normally circulate in pigs are called “variant” viruses when they are found in people. Influenza A H3N2 variant viruses (also known as “H3N2v” viruses) with the matrix (M) gene from the 2009 H1N1 pandemic virus were first detected in people in July 2011. H3N2 virus infections boost non-neutralizing H3N2 antibodies in middle-aged individuals, potentially leaving many of them in a perpetual state of 3c2.A H3N2 viral susceptibility.

 

"H3N2 Infection - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the H3N2 Infection pipeline landscape is provided which includes the disease overview and H3N2 Infection treatment guidelines. The assessment part of the report embraces, in depth H3N2 Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence in H3N2 Infection R&D. The therapies under development are focused on novel approaches to treat/improve in H3N2 Infection.
  • In September 2021, NanoFlu achieved the trial's primary endpoints, demonstrating non-inferior immunogenicity to Fluzone® Quadrivalent against all four influenza virus strains included in the vaccine, while also showing both enhanced wild-type hemagglutination-inhibiting antibody responses against homologous strains (22-66% increased) and six heterologous A/H3N2 strains (34-46% increased) as compared to Fluzone Quadrivalent.

H3N2 Infection Emerging Drug Chapters

This segment of the H3N2 Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

H3N2 Infection Emerging Drugs

 

NanoFlu: Novavax

NanoFlu is our quadrivalent nanoparticle influenza vaccine (qNIV) candidate, targeting seasonal flu. NanoFlu is designed using our recombinant technology, with 4 forms of wild-type hemagglutinin (HA) protein from the influenza virus as antigens. Antigens are organized into distinct nanoparticle complexes recognized by the immune system, working in concert with our Matrix-M™ adjuvant.

 

PrEP-001: PrEP Biopharm

PrEP-001, is an immunomodulator in Phase 2 for the prevention of influenza, influenza-like-illness and the common cold. These upper respiratory viral infections (URVIs) drive significant disease burden particularly for patients with underlying respiratory disorders (eg asthma and COPD) or weakened immune systems (eg the elderly). A nasally delivered powder containing a viral RNA surrogate, PrEP-001, triggers the innate immune system via the Rig-I, MDA5 and TLR3 receptors and is expected to provide a rapid, broad-spectrum prophylaxis against ~200 respiratory viruses. PrEP-001 is anticipated to be a first-to-market prophylactic nasal spray that creates a novel paradigm of prevention against these URVIs.

Further product details are provided in the report……..

H3N2 Infection: Therapeutic Assessment

This segment of the report provides insights about the different H3N2 Infection drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in H3N2 Infection

There are approx. 20+ key companies which are developing the therapies for H3N2 Infection. The companies which have their H3N2 Infection drug candidates in the most advanced stage, i.e. Phase II include  Ansun Biopharma.

 

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

H3N2 Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecule
  • Monoclonal Antibody
  • Immunotherapy
  • Vaccines

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

H3N2 Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses H3N2 Infection therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging H3N2 Infection drugs.

H3N2 Infection Report Insights

  • H3N2 Infection  Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

H3N2 Infection Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing H3N2 Infection drugs?
  • How many H3N2 Infection drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of H3N2 Infection?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the H3N2 Infection?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for H3N2 Infection and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

H3N2 Infection: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Treatment

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

H3N2 Infection  – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

DAS181: Ansun Biopharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

CD388: Cidara Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Astodrimer: Starpharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

H3N2 Infection  Key Companies

H3N2 Infection  Key Products

H3N2 Infection - Unmet Needs

H3N2 Infection - Market Drivers and Barriers

H3N2 Infection - Future Perspectives and Conclusion

H3N2 Infection  Analyst Views

H3N2 Infection  Key Companies

Appendix

List of Table

Table 1: Total Products for H3N2 Infection

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type                                              

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for H3N2 Infection

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Emergent BioSolutions
• Aphios
• Ansun Biopharma
• Starpharma
• Cidara Therapeutics
• Medicago
• Novavax
• PrEP Biopharm
• Sciogen
• CureVac

 

Forward to Friend

Need A Quote